BPC-157 IV Safety Study (2025): What the Human Study Found

Written by BPC-157 Research TeamEvidence checked 23 September 2026

A 2025 pilot study gave intravenous BPC-157 to two adults and reported no side effects and no clinically significant adverse changes in the blood markers it measured, over a short observation period. Because it involved only two people, both of whom had received intravenous BPC-157 before, it cannot establish the wider safety of BPC-157.

Why does this study matter?

This is the first published report of intravenous BPC-157 in humans, and one of only three full published human BPC-157 reports. A two-person study is the smallest possible step in safety research: it can flag obvious problems, but it cannot show that a substance is safe.

What were the researchers trying to find out?

Whether giving BPC-157 by intravenous infusion caused any measurable short-term changes in blood tests or vital signs, or any reported side effects.

How was the study carried out?

Two adults (a 58-year-old man and a 68-year-old woman, both of whom had received intravenous BPC-157 before the study) took part at a private Florida clinic, in a study approved by an ethics review board. Over three consecutive days, they received BPC-157 infusions and had blood tests and vital signs taken before and after each one. The blood tests covered markers of heart, liver, kidney and thyroid function, and blood sugar. Participants were asked about side effects at each appointment.

What did the study report?

The authors reported no clinically significant adverse changes in any of the measured blood markers, no changes in vital signs of concern, and no side effects reported by either participant during the observation period.

What did it report about safety?

Nothing of concern was reported, but a study of two people cannot establish the broader safety of BPC-157 or detect uncommon adverse effects. Both participants had also received intravenous BPC-157 before, which means the study may simply reflect people who had already tolerated it well. The authors themselves called for further research. Our BPC-157 side effects guide covers what has and hasn't been documented.

What can we conclude?

The study shows that two previously exposed adults received intravenous BPC-157 under monitoring without reported problems over a short period. It cannot show that BPC-157 is safe, in these participants long-term or in anyone else.

What are the study's limitations?

• Two participants. The smallest meaningful sample in human research, far too few to detect anything but the most common effects.
• Previous exposure. Both participants had tolerated intravenous BPC-157 before, which biases the study toward people unlikely to react.
• Short observation. Monitoring covered days, not weeks or months, so delayed effects could not be seen.
• No comparison group. There was no untreated group against which to compare the measurements.

How does this fit with other BPC-157 human research?

This is one of three recent full published human reports identified in our review, all sharing the same first author and journal. The wider human record also includes registered clinical trials and earlier studies reported only as abstracts. View all BPC-157 clinical trials and human studies →